Research Papers:
Fucoidan inhibits lymphangiogenesis by downregulating the expression of VEGFR3 and PROX1 in human lymphatic endothelial cells
Metrics: PDF 1996 views | HTML 2997 views | ?
Abstract
Yazong Yang1, Zixiang Gao1, Yanhong Ma1, Hongming Teng1, Zundong Liu1, Hengyun Wei1, Yanbing Lu1, Xiaofang Cheng1, Lin Hou2, Xiangyang Zou1
1Department of Biotechnology, Dalian Medical University, Dalian, 116044, China
2College of Life Sciences, Liaoning Normal University, Dalian, 116081, China
Correspondence to:
Xiangyang Zou, email: [email protected]
Keywords: fucoidan, lymphangiogenesis, lymphatic metastasis, lymphatic endothelial cells, PROX1
Received: January 14, 2016 Accepted: April 26, 2016 Published: May 18, 2016
ABSTRACT
Lymphangiogenesis is one of the promoters of tumor lymphatic metastasis. Fucoidan which is a fucose-enriched sulfated polysaccharide has effect on various pharmacological activities including anti-metastasis activity. However, the inhibitory effect of fucoidan on lymphangiogenesis remains unclear. Here, fucoidan extracted from U. pinnatifida sporophylls suppressed HLECs proliferation, migration and tube-like structure formation, and had inhibitory effect of tumor-induced lymphangiogenesis in vitro. Additionally, we found that fucoidan had a dose-dependent depressive effect on the expressions of PROX1, vascular endothelial growth factor receptor 3 (VEGFR3), NF-κB, phospho-PI3K and phospho-Akt in HLECs. Moreover, anti-lymphangiogenesis effect of fucoidan was assessed by using mouse tumor model. In summary, fucoidan inhibit tumor lymphangiogenesis and lymphatic metastasis by suppressing the NF-κB/PI3K/Akt signaling pathway through reduced levels of PROX1 and VEGFR3.
![Creative Commons License](/images/80x15.png)
PII: 9443